Pediatrix Medical Group (MD) Q2 2025 earnings summary

Executive summary

• Q2 2025 adjusted EBITDA was $73.2 million, exceeding expectations due to strong same-unit revenue growth, higher patient acuity, and favorable reimbursement factors, despite a 7% decline in consolidated revenue from portfolio restructuring and practice dispositions.

• Net income for Q2 2025 was $39.3 million, a significant improvement from a net loss of $153 million in Q2 2024, reflecting improved operations and the absence of prior year impairment charges.

• The company completed its exit from most office-based practices, focusing on hospital-based and maternal-fetal medicine services.

• Ongoing cost management and staffing reductions lowered G&A expenses, while incentive compensation increased due to higher results.

Financial highlights

• Q2 2025 net revenue was $468.8 million, down 7% year-over-year due to practice dispositions, but same-unit revenue grew 6.4% from higher patient acuity and volumes.

• Adjusted EPS for Q2 2025 was $0.53, up from $0.34 in Q2 2024; diluted EPS was $0.46, compared to a loss of $1.84 in Q2 2024.

• Operating cash flow for Q2 2025 was $138 million, with a quarter-end cash balance of $224.7 million and net debt just over $380 million.

• Net leverage stands just above 1.5x, using the midpoint of the updated adjusted EBITDA outlook.

• Accounts receivable DSO improved to 46.4 days, down over three days year-over-year due to better cash collections.

Outlook and guidance

• Full-year 2025 adjusted EBITDA guidance was raised and narrowed to $245 million–$255 million, reflecting strong Q2 performance and improved second-half visibility.

• Cash balance is expected to reach $350 million–$400 million by year-end 2025, absent other activities.

• Management expects funds from operations, cash on hand, and available credit to be sufficient for all obligations for at least the next 12 months.

• Margins are expected to remain stable through the end of 2025, with tougher comps anticipated in the second half.